ASX Release

7 June 2007

PharmAust LIMITED

PharmAust: Commonwealth Biotechnologies Inc completes acquisition of Tripos Discovery Research Ltd

PharmAust Limited (ASX:PAA) is pleased to announce that its drug discovery services investment company, Commonwealth Biotechnologies Inc (CBI) (NASDAQ: "CBTE"), completed the acquisition of British medicinal and synthetic chemistry company, Tripos Discovery Research Ltd.

The attached CBTE release reports, on a pro-forma basis, the acquisition of TDR represents an increase in CBI's 2006 revenues to AU$19.6M and upon closing increases CBI's cash position to AU$6.4M.

CBI shares closed trading at US$2.86 per share, valuing PharmAust's approximately 39.5% interest in CBI (2.15M shares) at AU$7.2M.

For more information see attached CBI announcement and Fact Sheet.

About PharmAust Limited
PharmAust Limited (ASX: PAA) is an Australian-owned diversified business focused on the manufacture and distribution of pharmaceutical & healthcare products and the provision of contract chemistry and drug discovery services.

- **About Commonwealth Biotechnologies, Inc (PharmAust 39.5%)** Commonwealth Biotechnologies Inc (CBI) specializes in life sciences R&D outsourcing and offers cutting-edge expertise and a complete array of the most current synthetic and analytical technologies in the areas of biodefense, laboratory support and contract research. CBI is well positioned to compete in the global market for drug discovery outsourcing with an experienced management team and highly trained scientific staff located in a world-class laboratory in Richmond, Virginia. For more information visit www.cbi-biotech.com.

- **PharmAust Manufacturing Pty Ltd (PharmAust 100%)** manufactures and markets therapeutic and non-therapeutic pharmaceutical products for Australian and overseas markets.

- **Epichem Pty Ltd (PharmAust 100%)** provides contract chemistry services alongside its own intellectual property-generating research activities.

For further information, contact:

Dr. Paul D'Sylva
Managing Director
PharmAust Limited
Tel: +1 858 699 0298
Email: paul@pharmaust.com
www.pharmaust.com

For further information contact:
Dr Paul D'Sylva
CEO
Commonwealth Biotechnologies, Inc.
858 699 0298

Commonwealth Biotechnologies, Inc. Completes Acquisition of Tripos Discovery Research Ltd

Richmond, VA (May 31, 2007). Commonwealth Biotechnologies, Inc (CBI), (NASDAQ: "CBTE") today announced that it has completed the acquisition of all of the outstanding capital stock of Tripos Discovery Research Limited, an English limited company ("TDR"). TDR is a world leader in medicinal and combinatorial chemistry and provides products and services that are complementary to CBI's existing offerings in biologics and custom peptides. The TDR acquisition provides CBI with a strategic production and sales and marketing site in the United Kingdom and is designed to accelerate the CBI's revenue and earnings growth. On a pro-forma basis, the acquisition of TDR represents an increase in CBI's 2006 revenues to $16.4 million and upon closing increases CBI's cash position to $5.36 million.

CBI's CEO, Dr Paul D'Sylva said, "CBI's acquisition of TDR is in line with our company's strategy to expand its drug discovery and development services in the field of pre-clinical chemistry and to extend the sale of its full suite of products and services into Europe. With the additional technical and commercial capabilities and resources that TDR brings, CBI anticipates that it will be able to grow a powerful, robust and diverse drug discovery services franchise servicing the growing global drug discovery market. Immediate cost and revenue synergies are expected from this transaction, which will accelerate CBI's continued growth."

Under the terms of the transaction, which was unanimously approved by CBI's Board of Directors, CBI has acquired all of the outstanding capital stock of TDR for an up-front payment of $350,000 followed by payments of up to $1.8 million from TDR receivables and billings. Concurrent with this transaction, TDR is entering into a sale-leaseback transaction with the South West of England Regional Development Authority ("SWERDA") for a 12 year lease of the facilities in Bude renewable every 3 years, and has been released from grant repayment obligations with the English Department of Trade and Industry and various inter-company advances from TDR's former parent organization, Tripos, Inc., a Utah corporation.

CBI's Chairman Dr Richard Freer said, "TDR is widely acknowledged as one of the premier drug discovery service companies in the world. With this transaction, the CBI group now offers comprehensive discovery products and services across the three major drug classes of biologics, peptides and small molecules. We at CBI are very excited about the potential this transaction has to grow our top line revenue and bottom line result."

About Tripos Discovery Research Limited

Tripos Discovery Research Ltd ("TDR") is a leading knowledge driven, drug discovery services business that provides pharmaceutical and biotechnology companies with novel approaches to drug discovery. Applying proprietary computational design and therapeutic medicinal chemistry tools and expertise, TDR is able to reduce drug discovery timelines by up to 30%. Since 1997, TDR has been offering compound libraries under the LeadQuest® brand, screening libraries under the LeadScreen® brand and custom de novo compound libraries under the LeadSelect® brand.

About Commonwealth Biotechnologies, Inc

The CBI group offers cutting-edge R&D products and services to the global life sciences industry. CBI now operates four distinct business units: (1) CBI Services, a discovery phase contract research organization, (2) Fairfax Identity Laboratories, a DNA reference business; (3) Mimotopes, a peptide and discovery chemistry business; and (4) TDR, a medicinal and synthetic discovery chemistry business. Collectively, CBI companies employ over 140 staff in world-class laboratories in the U.S., U.K., and Australia.

Forward Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, including statements regarding CBI's expectations, beliefs, intentions or strategies regarding the future. Forward-looking statements include, but are not limited to, express or implied statements regarding future revenues, revenue growth and profitability, and the markets for its services. All forward-looking statements included in this press release are based upon information available to CBI as of the date hereof. CBI assumes no obligation to update any such forward-looking statements. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially from those projected. Actual results may differ materially due to a number of factors including the perceived need for CBI's services, CBI's ability to efficiently incorporate TDR into its operations and macro economic conditions. These and other risks relating to CBI's business are set forth in CBI's Form 10-KSB filed with the Securities and Exchange Commission on March 30, 2007, and CBI's Form 10-QSBs and other reports filed from time to time with the Securities and Exchange Commission.

Market Data—May 2007
NASDAQ ("CBTE")
Share price as at 30 May, 2007: US$2.49
Shares Outstanding: 5.49M
PharmAust Interest: 2.15M
Market Cap: US$13.67M
52 week high: US$5.00
52 week low: US$1.81

Core Business
Drug Discovery & Development
Biosecurity
Forensics

Key Partnerships
U.S. Government
Genzyme Pharmaceuticals
Invitrogen
DynPort Vaccine Company
Thermo Fisher Scientific
Pepscan

Key Management
Paul D'Sylva
CEO
Richard Freer
Chairman and COO
Rob Harris
President
Tom Reynolds
Executive VP, S&T
Nick Hagan
CEO, Mimotopes
James Brennan
Vice President, Finance

Operating Businesses
CBI Services, Commonwealth Biotechnologies Services ("CBI Services") provides a wide array of life-science solutions in the areas of bio-defense, laboratory support and contract research. CBI has broad expertise in the most current analytical chemistries, microbiology applications and molecular biology technologies and has a reputation as a provider of novel and imaginative research and development solutions. CBI offers all services under the FDA's Good Laboratory Practices (GLP) Guidelines as codified in 21CFR 58. Selected Services are

COMMONWEALTH BIOTECHNOLOGIES, INC

CBI Overview

CBI was founded in 1992 to provide sophisticated research and development support services on a fee-for-service basis to the global biotechnology and pharmaceutical industry. Since 2004, CBI has pursued a strategy of acquiring or merging with complementary companies that extend its drug discovery capabilities and earnings potential. CBI now operates four distinct business units: (1) CBI Services, a discovery phase contract research organization, (2) Fairfax Identity Laboratories, a DNA reference business; (3) Mimotopes, a peptide and discovery chemistry business; and (4) TDR, a medicinal and synthetic chemistry company, and collectively employs over 140 staff in world-class laboratories based the U.S, U.K and Australia (See Figure 1).



Figure 1. CBI Global Territories

The Drug Discovery & Development Market

The market for drug discovery outsourcing was US$5.38b in 2005 and expected to grow at 20% per annum (p.a.) to reach US$7.2b in 2009 (Kalorama Information, 2006). Lead-optimization and Biology are the two fastest growing segments (over 20% pa), followed by Chemistry (10% pa) and Screening (6% pa). CBI now has offers products and services in each of these market segments and is well positioned to compete in this global market with its array of leading technologies and scientific staff coupled with a specialised sales and marketing team based in these key markets. The adoption of outsourcing by the pharmaceutical and biotechnology industries is driven by three major factors: Speed, Quality and Cost. CBI's range of proprietary technologies, know-how and experience give it a significant strategic advantage in the global drug discovery outsourcing market.

also offered under the FDA's Good Manufacturing Practices (cGMP) and Good Clinical Practices (cCMP) guidelines. The Quality Assurance office manages all regulated services.

Mimotopes Pty Ltd

("Mimotopes") is an industry leader with over 16 years experience in the development, synthesis and distribution of research grade peptides for the drug discovery industry. Mimotopes' patented synthesis technologies, state-of-the-art facilities and highly educated and experienced staff make it one of the leading research grade peptide synthesis companies in the world. Mimotopes' products and services are delivered to commercial clients on a fee-for-service basis (80%) and to discovery partners on a cost-recovery basis and IP sharing basis (20%). In 2006, Mimotopes developed significant partnerships with the key life science companies Invitrogen and Genzyme.

Tripos Discovery Research Ltd

("TDR") has extensive experience in computational design as well as high-throughput chemical synthesis, analysis and purification. TDR's competitive advantage lies in its unique ability to combine these offerings, particularly its proprietary informatics systems with state-of-the-art medicinal chemistry research. TDR's business can be broadly grouped into three categories: (1) Off the shelf and custom made compound libraries ('Drug Discovery Products'); (2) Screening, purification and quantitation services ('Drug Discovery Services'); and (3) Screening collections and early stage in-licensing ('Lead Discovery').

Fairfax Identity Laboratories

("FIL") has been at the forefront of DNA technology of profiling for identity since it open it's doors in 1990. FIL's rigorous standards guarantee beyond a reasonable doubt the credible evidence that clients demand. Their results affect decisions regarding criminal trials, paternity, immigration, estate settlement, adoption, and other issues of identity. FIL provides state of the art Forensics, Paternity and CODIS services to government and private concerns. FIL is accredited by the American Association of Blood Banks, the National Forensic Science Technology Center, the State of New York and CLIA. Its Directors have extensive laboratory and courtroom experience.

CBI Structure



Figure 2. CBI Organisation Chart

CBI Sales Analysis

CBI reported sales of US$6.53 million for the year ending December of 2006. Sales for Mimotopes over the same period were US$3.36 million and for TDR were US$6.55 million. On a pro-forma basis sales for 2006 represent an increase of 111% over 2005, when the company's sales were US$7.80 million. The addition of Mimotopes and TDR to CBI has helped the Company to continue the consecutive growth that it had achieved between 2003 and 2005. See Figure 3.



Figure 3. CBI Sales Growth